The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.

The invention relates to a compound or a salt thereof of formula [1],

##STR00001##

a fungicidal composition containing the compound or a salt thereof, a method for controlling plant disease occurring from phytopathogenic microorganism including the step of applying the fungicidal composition and a production method of the compound.

Compounds of the formula I ##STR00001## in which R.sup.1, R.sup.4, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Compounds of the formula I ##STR00001## in which R.sup.1, R.sup.4, R, X.sup.1, X.sup.2, X.sup.3, X.sup.4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

The present specification relates to a fluorine-based compound for a brancher, a polymer using the same, a polymer electrolyte membrane using the same, a fuel cell using the same, and a redox flow battery including the same.

Novel fluorinated benzenesulfonamides compounds of general formula (I) ##STR00001##
can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participate in disease progression.

Novel fluorinated benzenesulfonamides compounds of general formula (I) ##STR00001##
can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participate in disease progression.

The invention relates to a process for producing 4,4′-dichlorodiphenyl sulfone, comprising: (I) reacting thionyl chloride, chlorobenzene and aluminum chloride forming an intermediate reaction product and hydrogen chloride; (II) mixing aqueous hydrochloric acid and the intermediate reaction product to obtain an organic phase comprising 4,4′-dichlorodiphenyl sulfoxide and an aqueous phase; (III) cooling the organic phase to a temperature below the saturation point of 4,4′-dichlorodiphenyl sulfoxide to obtain a suspension; (IV) solid-liquid-separation of the suspension to obtain crystallized 4,4′-dichlorodiphenyl sulfoxide, and mother liquor; (V) washing the crystallized 4,4′-dichlorodiphenyl sulfoxide with a carboxylic acid to obtain carboxylic acid-wet 4,4′-dichlorodiphenyl sulfoxide; (VI) reacting the washed 4,4′-dichlorodiphenyl sulfoxide and an oxidizing agent in a carboxylic acid as solvent to obtain a reaction mixture comprising 4,4′-dichlorodiphenyl sulfone and carboxylic acid; (VII) separating the reaction mixture comprising 4,4′-dichlorodiphenyl sulfone and carboxylic acid into a residual moisture comprising 4,4′-dichlorodiphenyl sulfone as crude product and a liquid phase comprising carboxylic acid.

The invention relates to a process for producing 4,4′-dichlorodiphenyl sulfone, comprising: (I) reacting thionyl chloride, chlorobenzene and aluminum chloride forming an intermediate reaction product and hydrogen chloride; (II) mixing aqueous hydrochloric acid and the intermediate reaction product to obtain an organic phase comprising 4,4′-dichlorodiphenyl sulfoxide and an aqueous phase; (III) cooling the organic phase to a temperature below the saturation point of 4,4′-dichlorodiphenyl sulfoxide to obtain a suspension; (IV) solid-liquid-separation of the suspension to obtain crystallized 4,4′-dichlorodiphenyl sulfoxide, and mother liquor; (V) washing the crystallized 4,4′-dichlorodiphenyl sulfoxide with a carboxylic acid to obtain carboxylic acid-wet 4,4′-dichlorodiphenyl sulfoxide; (VI) reacting the washed 4,4′-dichlorodiphenyl sulfoxide and an oxidizing agent in a carboxylic acid as solvent to obtain a reaction mixture comprising 4,4′-dichlorodiphenyl sulfone and carboxylic acid; (VII) separating the reaction mixture comprising 4,4′-dichlorodiphenyl sulfone and carboxylic acid into a residual moisture comprising 4,4′-dichlorodiphenyl sulfone as crude product and a liquid phase comprising carboxylic acid.

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders. ##STR00001##